Deslorelin

Deslorelin Peptide Vials

• CAS Number: 57773-65-6
• Molar Mass: 1282.475 g·mol−1
• Chemical Formula: C64H83N17O12
• IUPAC Name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

Introduction

Deslorelin Vials are a sophisticated research product meticulously developed for scientific investigations, not intended for human consumption. The vials contain Deslorelin, a potent peptide synthesized to meet high research standards, making it invaluable for various experiments.

Key Characteristics

With exceptional purity and stability, Deslorelin Vials provide researchers with a dependable source of Deslorelin. The formulation ensures optimal experimental conditions, enhancing research accuracy and reproducibility.

Research Applications

Deslorelin Vials are widely used in research, leveraging the unique properties of Deslorelin for experimental purposes.

Research Benefits

Deslorelin and Infertility

Studies suggest that Deslorelin may have implications for infertility research. Its ability to modulate reproductive hormones makes it a key focus in exploring infertility-related mechanisms and potential treatments.

Deslorelin and Precocious Puberty

Deslorelin has been studied for its potential to suppress early puberty, providing insights into hormonal regulation. Research continues to investigate its effects on hormonal pathways and puberty onset.

Deslorelin and Prostate Cancer

Research suggests that the peptide may help modulate hormonal pathways in prostate cancer, supporting further study into its therapeutic potential.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards outlined by the Animal Welfare Act (AWA).

Our informational content is designed for research-oriented insights and should not replace individual analysis and verification from credible sources before making purchasing decisions.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction is our top priority. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are not intended for veterinary or human use.

References

• Herbert, C. A., Trigg, T. E., Renfree, M. B., Shaw, G., Eckery, D. C., & Cooper, D. W. (2005). Long-term effects of deslorelin implants on reproduction in the female tammar wallaby (Macropus eugenii). Reproduction, 129(3), 361-369. Retrieved Nov 14, 2023, from https://doi.org/10.1530/rep.1.00432.
• Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr. (1991). Adult height in precocious puberty after long-term treatment with Deslorelin. J Clin Endocrinol Metab, 73(6), 1235-40. doi: 10.1210/jcem-73-6-1235. PMID: 1955504.
• Sundaram S, Durairaj C, Kadam R, Kompella UB. (2009). Luteinizing hormone-releasing hormone receptor-targeted Deslorelin-docetaxel conjugate enhances the efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther, 8(6), 1655-65. doi: 10.1158/1535-7163.MCT-08-0988. PMID: 19509261.